Loading...
•
Dec 31, 2023
Verve Therapeutics Q4 2023 Earnings Report
Verve Therapeutics reported financial results and pipeline updates.
Key Takeaways
Verve Therapeutics reported a net loss of $48.4 million for Q4 2023, with cash, cash equivalents, and marketable securities totaling $624.0 million as of December 31, 2023, expected to fund operations into late 2026. The company made progress with its clinical programs, including VERVE-101, VERVE-102, and VERVE-201, and anticipates having three in vivo gene editing programs in the clinic in 2024.
First human proof-of-concept data for in vivo base editing demonstrated in Heart-1 Phase 1b clinical trial of VERVE-101.
Three clinical-stage programs targeting PCSK9 and ANGPTL3 are expected in 2024.
IND clearance received from U.S. FDA for VERVE-101.
Cash, cash equivalents, and marketable securities totaled $624 million, providing a cash runway into late 2026.
Verve Therapeutics
Verve Therapeutics
Verve Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Verve Therapeutics anticipates several milestones in 2024, including dosing the first patient in the U.S. in the VERVE-101 trial, completing enrollment in the Phase 1b trial of VERVE-101, initiating the Heart-2 Phase 1b trial for VERVE-102, and initiating a Phase 1b trial for VERVE-201.
Positive Outlook
- Dose the first patient in the United States in the VERVE-101 trial.
- Complete enrollment in the ongoing Phase 1b trial of VERVE-101 and provide a data update.
- Initiate the Heart-2 Phase 1b trial for VERVE-102 targeting PCSK9 in the first half of the year.
- Initiate a Phase 1b trial for VERVE-201 targeting ANGPTL3 in the second half of the year.
- Have three in vivo gene editing programs in the clinic in 2024.